# Suman Subramanian

> Suman Subramanian is a biopharmaceutical commercial executive and operator who became Chief Business Officer of ABL Ascend Advanced Therapies in August 2026. Across roles at West Pharmaceutical Services, Catalent Cell & Gene Therapy and Stevanato Group, his public work has centered on turning complicated development, manufacturing and supply networks into simpler customer programs. He holds graduate training in pharmaceutical systems management and bioinformatics, speaks and writes six languages, and now leads ABL Ascend's global business development, marketing and strategic partnership functions.

- **Role:** Chief Business Officer at ABL Ascend Advanced Therapies
- **Organizations:** ABL Ascend Advanced Therapies, Ascend Advanced Therapies, ABL Inc., Stevanato Group, Catalent Cell & Gene Therapy, West Pharmaceutical Services
- **Education:** MSc in Pharmaceutical Systems Management, Rutgers University, Bioinformatics studies, New Jersey Institute of Technology
- **Known for:** Entrusted with global commercial leadership at ABL Ascend across business development, marketing and strategic partnerships., Built nearly two decades of experience supporting emerging biotechnology companies and large pharmaceutical organizations., Helped integrate a major API manufacturing facility into a supply network of more than 3,600 nodes during his time at West Pharmaceutical Services.

## Career timeline

- **Before 2022** — Spent six years in multiple roles at West Pharmaceutical Services; a published biography says one assignment involved integrating a major API manufacturing facility into a supply network with more than 3,600 nodes in Kalamazoo, Michigan, and Puerto Rico.
- **2022** — Joined Catalent Cell & Gene Therapy Commercial Operations, integrating commercial strategy and partnerships and leading its business-unit commercial operations council.
- **2024-04** — Appeared on The BioInsights Podcast and in Cell & Gene Therapy Insights to discuss scalable manufacturing, supply resilience, platform processes and cost predictability in gene therapy.
- **2025-2026** — Served as Vice President of Integrated Solutions at Stevanato Group.
- **2026-08** — Appointed Chief Business Officer of ABL Ascend Advanced Therapies, leading global business development, marketing and strategic partnership functions.

## Achievements

- Entrusted with global commercial leadership at ABL Ascend across business development, marketing and strategic partnerships.
- Built nearly two decades of experience supporting emerging biotechnology companies and large pharmaceutical organizations.
- Helped integrate a major API manufacturing facility into a supply network of more than 3,600 nodes during his time at West Pharmaceutical Services.
- Led commercial-operations integration and partnership work for Catalent Cell & Gene Therapy.
- Published and recorded a detailed industry interview on scaling gene therapy manufacturing while improving predictability and reducing waste.

## Latest updates

- **2026-08** — Appointed Chief Business Officer of ABL Ascend Advanced Therapies.
- **2024-04** — Published a Cell & Gene Therapy Insights interview and appeared on The BioInsights Podcast about gene-therapy supply and scalable manufacturing.

## Links

- Website: https://www.ascend-adv.com
- LinkedIn: https://www.linkedin.com/in/suman-subramanian-37172417

---

Profile page: https://yespress.io/suman-subramanian
Published by YesPress — https://yespress.io
Last updated: 2026-09-28